Combined use of omeprazole and a novel antioxidative cytoprotectant for the treatment of peptic ulcer. Facilitation of ulcer healing in experimental animals.
Peptic ulcer and gastroesophageal reflux are common acid-peptic related diseases. The pathophysiology of peptic ulcer disease has been centered on an imbalance between aggressive and defensive factors. This study was conducted to examine whether the combined use of omeprazole (CAS 73590-58-6), a proton pump inhibitor, and DA-9601, a novel anti-ulcer formulation of the extract of Artemisia asiatica Nakai, has synergistic effects on various peptic ulcers and gastroesophageal reflux diseases in animal models. An optimal combination ratio of omeprazole and DA-9601 was investigated in an acetic acid-induced ulcer model. In the results, oral pretreatment with omeprazole and DA-9601 (combination ratio, 1:3) significantly reduced alcohol-, indometacin-, acetic acid-, and cysteamine-induced gastrointestinal lesions in a synergistical manner in rats. The combination treatment also significantly attenuated the gross and histopathological lesions in an experimental reflux esophagitis model as compared to the single treatment of omeprazole or DA-9601. In an alcohol-induced gastritis model, the combined treatment resulted in a significant decrease in lipid peroxidation with concomitant increases in glutathione content and prostaglandin E2 level, which was proportional to the inhibitory effect of the combination therapy. These results suggest that the combined therapy with omeprazole and DA-9601, a cytoprotectant, can be beneficial for the treatment of peptic ulcer and reflux esophagitis.
Kim
Ju Mi
JM
Research Laboratories, Dong-A Pharmaceutical Company, Kyunggi-do, Korea.
Choi
Seul Min
SM
Kim
Dong Hwan
DH
Oh
Tae Young
TY
Ahn
Byoung Ok
BO
Kwon
Jong Won
JW
Kim
Won Bae
WB
D019342:Acetic Acid; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D019306:Artemisia / Q000737:chemistry*; D002492:Central Nervous System Depressants; D003543:Cysteamine; D004359:Drug Therapy, Combination; D004942:Esophagitis, Peptic / Q000139:chemically induced / Q000188:drug therapy; D000431:Ethanol; D005753:Gastric Mucosa / Q000473:pathology; D005756:Gastritis / Q000139:chemically induced / Q000188:drug therapy; D007213:Indomethacin; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000473:pathology; D010936:Plant Extracts / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D000975:Antioxidants; D002492:Central Nervous System Depressants; D010936:Plant Extracts; D000431:Ethanol; D003543:Cysteamine; D009853:Omeprazole; D019342:Acetic Acid; D007213:Indomethacin